This segment focuses on developing personalized neoantigen cancer vaccines, such as VB10.NEO, to target solid tumors. The approach involves identifying unique mutations in a patient's tumor and creating a vaccine that stimulates the immune system to recognize and destroy cancer cells. Research and development activities include preclinical studies, Phase 1/2a clinical trials for melanoma, lung, head and neck, renal, and bladder cancers, and collaborations with partners like Roche and Nektar Therapeutics. The goal is to provide effective and targeted treatments for patients with various types of cancer, improving patient outcomes and survival rates. Future opportunities include expanding the application of neoantigen vaccines to other cancer types and developing combination therapies with checkpoint inhibitors and other immunomodulatory agents.

This segment is dedicated to the discovery and development of novel vaccines for infectious diseases. The company leverages its proprietary Vaccibody technology platform to design vaccines that elicit strong and long-lasting immune responses. Research and development efforts include preclinical studies and clinical trials to evaluate the safety and efficacy of vaccine candidates against various infectious agents. The focus is on developing vaccines that can prevent or treat diseases with high unmet medical needs, such as viral infections and bacterial infections. Future opportunities include expanding the vaccine pipeline to address emerging infectious disease threats and developing combination vaccines that provide protection against multiple pathogens.

This segment is focused on the development of therapeutic vaccines, including VB10.16, designed to treat existing diseases, particularly those induced by human papilloma virus 16 (HPV16), such as cervical cancer. The research and development activities involve clinical trials to assess the vaccine's ability to stimulate an immune response that can eliminate HPV16-infected cells and prevent disease progression. The therapeutic approach aims to provide a targeted treatment option for patients with HPV16-related malignancies, improving patient outcomes and quality of life. Future opportunities include expanding the application of therapeutic vaccines to other HPV-related diseases and developing combination therapies with other cancer treatments.